sorafenib has been researched along with elisidepsin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (elisidepsin) | Trials (elisidepsin) | Recent Studies (post-2010) (elisidepsin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 21 | 5 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angenstein, F; Baldauf, L; Daniel, EA; Kirches, E; Mawrin, C; Pachow, D; Scholz, J; Stork, O; Tuchen, M; Wilisch-Neumann, A | 1 |
1 other study(ies) available for sorafenib and elisidepsin
| Article | Year |
|---|---|
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Depsipeptides; Disease Models, Animal; Humans; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |